Biomarker

My current area of practice is in the twenty-three-bed surgical intensive care unit (SICU) at Vanderbilt University Medical Center (VUMC). It is a Level I trauma center and tertiary care center that provides some of the complex care in middle Tennessee. One major patient population frequently admitted to the SICU are patients diagnosed with acute respiratory distress syndrome (ARDS). ARDS is a complicated lung disorder that causes profound hypoxia. It is seen in up to 10% of critically ill patients

Autism is a neurological developmental disorder that characterized by deficits in social interaction, social communication, restricted and repetitive interests, and behavioral patterns. Symptoms of autism manifested in children usually by the age of 3 (Wang et al., 2014) It also characterized by impaired language and social skills, and restricted areas of interest. Additional features may include poor eye contact, repetitive behavior, sensory modulatory dysfunction, and varying levels of cognition

cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting, which was conducted by Daniela Perani, Chiara Cerami, Silvia Paola Caminiti, Roberto Santangelo, Elisabetta Coppi, Laura Ferrari, Patrizia Pinto, Gabriella Passerine, Andrea Falini, Sandro Iannaccone, Stefano Francesco Cappa, Giancarlo Comi, Luigi Gianolli, and Giuseppe Magnani. The study was designed to evaluate the role of support that molecular and structural biomarkers which is CSF protein

early detection metabolic biomarkers for hypoxia-induced AKI. Goals: ¥ The goal is to subject 24 mice to 3 hours of 10% Oxygen (normal Oxygen is about 22%) to mimic the symptoms of hypoxia-induced AKI in humans.

Along with potential biomarkers, research has focused on how to best treat patients with sepsis and septic shock. The current recommendations include giving IV antibiotics within 1 hour of recognition of sepsis and a minimum of 30 mL/kg of IV crystalloid fluid within the first

Salivary Biomarkers Introduction: Worldwide, tobacco-use continues to be one of the leading causes of preventable death and has been estimated to kill more than five million people annually1. Lately, the epidemic of tobacco-use has shifted from developed to developing countries2. It is estimated that by 2030 almost 10 million people will die from tobacco-use per year, with 70% of these deaths occurring in developing countries. India accounts for one-sixth of the tobacco-related illnesses

Impact Statement: The potential impact of our research study on the reduction or elimination of the disproportionate effects of prostate cancer in AA population is on several grounds. Using our innovative molecular screening approaches it is for the first time we are evaluating the prevalence of prostate cancer specific molecular markers using the whole-mount prostate tissue of AA population on a large cohort of 500 AA men with prostate cancer. So far, no study has included such a large number of

cancer kills a woman every 7 minutes due to an international inadequacy in breast cancer diagnoses (Saxena, 2017). Could these tragic deaths be prevented by more accessible means of public health care? The patenting of breast cancer genes and biomarkers by private corporations causes exclusivity and secrecy surrounding cancer research, denying the public of their right to proper health care. An increased number of patents are being approved by the US Patent and Trademark Office regarding procedures

Doctors are responsible for providing the patients with pain killers whether they are telling the truth or not because there is no feasible biomarker for pain that can disprove it. Electroencephalography (EEG) techniques were used in the study that demonstrated a promising source of physiological biomarkers that accompanied chronic pain. Discovery of this biomarker will not only help with substance abuse but also help with diagnosing, finding a proper treatment and help with developing new therapeutic

biomolecules which potential to be used in diagnostic procedures of the disease. One of the promising biomarkers for pre-eclampsia is PlGF, an angiogenic biomarker. 6,7,8 Angiogenesis is the key process for proper development of the placental vascular system. Angiogenic factors and their receptors are believed to play roles in the pathogenesis of pre-eclampsia, thus made them be potential candidate biomarkers for pre-eclampsia. The most widely studied serum markers for pre-eclampsia are VEGF and PlGF, and